Friday, September 29, 2023


Biotechnology News Magazine

GenScript Launches Expedited mRNA Service for Research and Pre-Clinical Applications

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

GenScript USA Inc., the world’s leading life-science research tools and services provider, announced the availability of a new research use only (RUO) and pre-clinical messenger RNA (mRNA) synthesis service for biopharma research and development teams. By applying decades of experience in molecular biology, GenScript now offers a single-vendor gene-to-mRNA service that delivers custom mRNA within six to eight weeks.

mRNA provides new therapeutic opportunities for a range of diseases, and scientists need expedited, access to robust, custom mRNA to synthesize the proteins used to engineer personalized medicines. But, until now, development of mRNA involved contracting with several different specialist suppliers.

In contrast, GenScript’s IVT mRNA service spans the entire workflow, from gene synthesis to mRNA production. This simple and expedited mRNA manufacturing workflow expands the possibilities for personalized medicines such as patient-specific cancer vaccines or protein replacement for rare diseases.

“GenScript brings decades of deep technical expertise and a reputation for routinely producing customized nucleic acids for biopharma, academic, and industry clients worldwide,” said Ray Chen, PhD, president of GenScript USA Life Science Group. “The new IVT mRNA production service solves mRNA researchers’ challenges of sourcing and communicating among multiple vendors and de-risks the synthesis of highly optimized mRNA designs.”

Service highlights

GenScript accelerates mRNA research with optimized mRNA production workflow — from gene to mRNA in 6-8 weeks

Eliminates the need to provide mRNA expression vectors: just provide open reading frames (ORFs); GenScript will manage all the steps to successful custom mRNA synthesis
GenScript’s integrated gene synthesis, linearization, and IVT process ensures high mRNA integrity and uniform poly(A) tails which results in enhanced expression efficiency.
mRNAs produced at GenScript are optimized with our proprietary production platform, ensuring the quality and expression efficiency of your mRNA.

Where to learn more

Visit GenScript’s IVT mRNA services information page.
Download the GenScript IVT mRNA therapy modalities infographic poster.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine